Geriatrics Section

Dr. Michelle Braun from the Alzheimer's Association of Wisconsin "High Octane Brain"

Poverty and Aging in America December 2022.pptx

Social Services Section

Case Management Section

Operations & Finance Section

Geographic Information Systems Section

Neurology-Cognition Section

02/22/2021

1. Arboleda-Velasquez, J.F., et al., Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report. Nature Medicine, 2019. 25(11): p. 1680-1683.

2. Arce Renteria, M., et al., Illiteracy, dementia risk, and cognitive trajectories among older adults with low education. Neurology, 2019. 93(24): p. e2247-e2256.

3. Besser, L.M. and J.E. Galvin, Diagnostic experience reported by caregivers of patients with frontotemporal degeneration. Neurol Clin Pract, 2020. 10(4): p. 298-306.

4. Bieniek, K.F., et al., Association between contact sports participation and chronic traumatic encephalopathy: a retrospective cohort study. Brain Pathology, 2019. 30(1): p. 63-74.

5. Conen, D., et al., Relationships of Overt and Silent Brain Lesions With Cognitive Function in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2019. 73(9): p. 989-999.

6. Demmer, R.T., et al., Periodontal disease and incident dementia: The Atherosclerosis Risk in Communities Study (ARIC). Neurology, 2020. 95(12): p. e1660-e1671.

7. Devanand, D.P., et al., Intact global cognitive and olfactory ability predicts lack of transition to dementia. Alzheimers Dement, 2020. 16(2): p. 326-334.

8. Dhana, K., et al., Healthy lifestyle and the risk of Alzheimer dementia. Neurology, 2020. 95(4): p. e374-e383.

9. Ducharme, S., et al., Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. Brain, 2020. 143(6): p. 1632-1650.

10.Feustel, A.C., et al., Risks and benefits of unapproved disease-modifying treatments for neurodegenerative disease. Neurology, 2020. 94(1): p. e1-e14.

11. Figueiro, M.G., et al., Effects of a Tailored Lighting Intervention on Sleep Quality, Rest–Activity, Mood, and Behavior in Older Adults With Alzheimer Disease and Related Dementias: A Randomized Clinical Trial. Journal of Clinical Sleep Medicine, 2019. 15(12): p. 1757-1767.

12. Fink, H.A., et al., Benefits and Harms of Prescription Drugs and Supplements for Treatment of Clinical Alzheimer-Type Dementia. Annals of Internal Medicine, 2020. 172(10): p. 656-668.

13. Grande, G., et al., Association Between Cardiovascular Disease and Long-term Exposure to Air Pollution With the Risk of Dementia. JAMA Neurol, 2020. 77(7): p. 801-809.

14. Haaksma, M.L., et al., Survival time tool to guide care planning in people with dementia. Neurology, 2020. 94(5): p. e538-e548.

15. Hemmy, L.S., et al., Brief Cognitive Tests for Distinguishing Clinical Alzheimer-Type Dementia From Mild Cognitive Impairment or Normal Cognition in Older Adults With Suspected Cognitive Impairment. Ann Intern Med, 2020. 172(10): p. 678-687.

16. Huyer, G., et al., Five-year risk of admission to long-term care home and death for older adults given a new diagnosis of dementia: a population-based retrospective cohort study. CMAJ, 2020. 192(16): p. E422-E430.

17. Iadecola, C. and N.S. Parikh, Statins and Cognitive Impairment. Journal of the American College of Cardiology, 2019. 74(21): p. 2569-2571.

18.  Isaacson, R.S., et al., Individualized clinical management of patients at risk for Alzheimer's dementia. Alzheimers Dement, 2019. 15(12): p. 1588-1602.

19. Kansal, K., et al., Survival in Frontotemporal Dementia Phenotypes: A Meta-Analysis. Dement Geriatr Cogn Disord, 2016. 41(1-2): p. 109-22.

20. Khan, B.A., et al., Biomarkers of Delirium Duration and Delirium Severity in the ICU. Crit Care Med, 2020. 48(3): p. 353-361.

21. Lam, J., J. Hlavka, and S. Mattke, The Potential Emergence of Disease-Modifying Treatments for Alzheimer Disease: The Role of Primary Care in Managing the Patient Journey. J Am Board Fam Med, 2019. 32(6): p. 931-940.

22. Lane, C.A., et al., Associations Between Vascular Risk Across Adulthood and Brain Pathology in Late Life. JAMA Neurology, 2020. 77(2): p. 175.

23. Licher, S., et al., Genetic predisposition, modifiable-risk-factor profile and long-term dementia risk in the general population. Nat Med, 2019. 25(9): p. 1364-1369.

24. Livingston, G., et al., Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet, 2020. 396(10248): p. 413-446.

25. Mamiya, Y., et al., The Pareidolia Test: A Simple Neuropsychological Test Measuring Visual Hallucination-Like Illusions. PLoS One, 2016. 11(5): p. e0154713.

26. Mansfield, E., et al., Primary Care Physicians' Perceived Barriers to Optimal Dementia Care: A Systematic Review. Gerontologist, 2019. 59(6): p. e697-e708.

27. Matar, E., et al., Cognitive fluctuations in Lewy body dementia: towards a pathophysiological framework. Brain, 2020. 143(1): p. 31-46.

28. Maust, D.T., et al., Predicting Risk of Potentially Preventable Hospitalization in Older Adults with Dementia. Journal of the American Geriatrics Society, 2019. 67(10): p. 2077-2084.

29. McCleery, J., et al., When is Alzheimer's not dementia-Cochrane commentary on The National Institute on Ageing and Alzheimer's Association Research Framework for Alzheimer's Disease. Age Ageing, 2019. 48(2): p. 174-177.

30. McKeith, I.G., et al., Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology, 2017. 80(1): p. 88-100.

31. Nagpal, R., et al., Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer's disease markers in subjects with mild cognitive impairment. EBioMedicine, 2019. 47: p. 529-542.

32. Rabin, J.S., et al., Associations of Physical Activity and beta-Amyloid With Longitudinal Cognition and Neurodegeneration in Clinically Normal Older Adults. JAMA Neurol, 2019.

33. Reuben, D.B., et al., Patient and Caregiver Benefit From a Comprehensive Dementia Care Program: 1-Year Results From the UCLA Alzheimer's and Dementia Care Program. J Am Geriatr Soc, 2019. 67(11): p. 2267-2273.

34. Rouch, L., et al., Systolic blood pressure postural changes variability is associated with greater dementia risk. Neurology, 2020. 95(14): p. e1932-e1940.

35. Ryan, J., et al., Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline. Neurology, 2020. 95(3): p. e320-e331.

36. Samaras, K., et al., Effects of Statins on Memory, Cognition, and Brain Volume in the Elderly. J Am Coll Cardiol, 2019. 74(21): p. 2554-2568.

37. Sasannejad, C., E.W. Ely, and S. Lahiri, Long-term cognitive impairment after acute respiratory distress syndrome: a review of clinical impact and pathophysiological mechanisms. Critical Care, 2019. 23(1).

38. Seshadri, S., Prevention of Dementia-Thinking Beyond the Age and Amyloid Boxes. JAMA Neurol, 2020. 77(2): p. 160-161.

39. Shah, R.C. and D.A. Bennett, Physicians and Alzheimer Dementia: Past, Present, and Future. Ann Intern Med, 2020. 172(10): p. 695-696.

40. Sims, R., M. Hill, and J. Williams, The multiplex model of the genetics of Alzheimer's disease. Nat Neurosci, 2020. 23(3): p. 311-322.

41. Slot, R.E.R., et al., Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia. Alzheimer's & Dementia, 2019. 15(3): p. 465-476.

42. Song, H., et al., Association of Stress-Related Disorders With Subsequent Neurodegenerative Diseases. JAMA Neurology, 2020. 77(6): p. 700.

43. Tari, A.R., et al., Are the neuroprotective effects of exercise training systemically mediated? Prog Cardiovasc Dis, 2019. 62(2): p. 94-101.

44. Toepper, M. and M. Falkenstein, Driving Fitness in Different Forms of Dementia: An Update. J Am Geriatr Soc, 2019. 67(10): p. 2186-2192.

45. Townley, R.A., et al., Progressive dysexecutive syndrome due to Alzheimer's disease: a description of 55 cases and comparison to other phenotypes. Brain Commun, 2020. 2(1): p. fcaa068.

46. Valente, E.S., et al., Phenocopy syndrome of behavioral variant frontotemporal dementia: a systematic review. Alzheimer's Research & Therapy, 2019. 11(1).

47. van Maurik, I.S., et al., Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project. Alzheimer's Research & Therapy, 2019. 11(1).

48. Wesley, S.F. and D. Ferguson, Autoimmune Encephalitides and Rapidly Progressive Dementias. Semin Neurol, 2019. 39(2): p. 283-292.

49. Westenberger, A. and C. Klein, Essential phenotypes of NOTCH2NLC-related repeat expansion disorder. Brain, 2020. 143(1): p. 5-8.

50. Younan, D., et al., Particulate matter and episodic memory decline mediated by early neuroanatomic biomarkers of Alzheimer's disease. Brain, 2020. 143(1): p. 289-302.

51.  Younes, L., et al., Identifying Changepoints in Biomarkers During the Preclinical Phase of Alzheimer's Disease. Front Aging Neurosci, 2019. 11: p. 74.